Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$64000.0.

  • Sangamo Therapeutics' Cash from Investing Activities fell 12746.78% to -$64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 9832.77%. This contributed to the annual value of $37.5 million for FY2024, which is 7555.93% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Cash from Investing Activities of -$64000.0 as of Q3 2025, which was down 12746.78% from -$24000.0 recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Cash from Investing Activities high stood at $89.3 million for Q2 2021, and its period low was -$13.5 million during Q3 2022.
  • In the last 5 years, Sangamo Therapeutics' Cash from Investing Activities had a median value of $35.8 million in 2023 and averaged $27.7 million.
  • In the last 5 years, Sangamo Therapeutics' Cash from Investing Activities soared by 199548.39% in 2023 and then crashed by 12746.78% in 2025.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Cash from Investing Activities stood at $52.6 million in 2021, then dropped by 19.04% to $42.6 million in 2022, then decreased by 11.51% to $37.7 million in 2023, then plummeted by 96.49% to $1.3 million in 2024, then tumbled by 104.83% to -$64000.0 in 2025.
  • Its Cash from Investing Activities stands at -$64000.0 for Q3 2025, versus -$24000.0 for Q2 2025 and $1.3 million for Q4 2024.